Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...
-- Three medical experts will join members of Syros’ leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the...
– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 56.5 | 57.5 | 54.5 | 27821 | 55.5 | DE |
4 | 0 | 0 | 56.5 | 64.5 | 52.5 | 44998 | 57.48441053 | DE |
12 | 6 | 11.8811881188 | 50.5 | 65.81 | 50.5 | 59958 | 57.27862467 | DE |
26 | 14 | 32.9411764706 | 42.5 | 65.81 | 36.2 | 65735 | 48.03669148 | DE |
52 | 25.75 | 83.7398373984 | 30.75 | 65.81 | 27.15 | 63835 | 42.73749478 | DE |
156 | 35.2 | 165.258215962 | 21.3 | 65.81 | 18.12 | 60133 | 33.28174661 | DE |
260 | 32.5 | 135.416666667 | 24 | 65.81 | 4.808 | 97284 | 23.80623277 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.